Do you have Type 2 Diabetes and kidney problems?
The purpose of the FIGARO-DKD clinical research study is to evaluate whether adding an investigational medication called finerenone to regular treatment is safe and effective to help reduce cardiovascular complications like heart disease or stroke in patients with type 2 diabetes and diabetic kidney disease.
The study will also look at whether the addition of finerenone to regular treatment may help slow the progression of kidney disease.
Anticipated date that enrolment will close: June 2018
Who can take part
People who meet the following criteria may be eligible to be part of the study:
- People with type 2 diabetes
- People with Diabetic Kidney Disease (confirmed with blood and urine tests)
- Currently taking medication for high blood pressure
- If you are aged over 18
What is involved for you
- Blood and urine samples